Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split
Brief: Acurx Pharmaceuticals Announces Presentation Of Results From Leiden University Medical Center Public-Private Partnership For Its DNA pol IIIC Inhibitors
Brief: Acurx Pharmaceuticals Inc Files For Resale Of Up To 10.9 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Acurx Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Acurx Pharmaceuticals Q1 Net Income USD -2.1 Million
Acurx Pharmaceuticals Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2025 Financial Results
Acurx Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Acurx Pharmaceuticals Announces Closing of $1.1 Million Registered Direct Offering
Brief: Acurx Pharmaceuticals Announces $1.1 Million Registered Direct Offering
Brief: Acurx Pharmaceuticals Announces Closing Of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Acurx Pharmaceuticals Announces $2.5 Mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Acurx Receives Positive Regulatory Guidance From EMA For Ibezapolstat Phase 3 Program For CDI
Brief: FDA Provides Positive Feedback On Acurx's CMC Plan For Phase 3